 The U.S. Food and Drug Administration, FDA, along with the Center for Research on Complex Generics, CRCG, held a virtual public workshop on November 30, 2021 to discuss the use of model integrated evidence, MIE, to demonstrate bioequivalence for long-acting injectable and implantable drug products. The workshop brought together experts from the pharmaceutical industry, academia, and the FDA to explore the potential benefits of using MIE for bioequivalence testing of these products. The presentations and panel discussions focused on topics such as challenges and opportunities in developing and assessing generic LAI products, current status of utilizing MIE, recent research progress in utilizing MIE for generic LAI products, alternative designs for bioequivalence studies of LAI products, and model validation slash verification strategies associated with different types of MIE approaches. This article was authored by Yucheng Gong, Peijue Zhang, Mayang Yun, and others. We are article.tv, links in the description below.